Literature DB >> 2340205

Psoralen/UV inactivation of HIV-1-infected cells for use in cytologic and immunologic procedures.

A J Watson1, J Klaniecki, C V Hanson.   

Abstract

A rapid procedure for the inactivation of HIV-1-infected cells using psoralen and ultraviolet (UV) light is described. Exposure of HIV-1-infected cells to 5 micrograms/ml psoralen followed by UV irradiation (320-380 nm) for 5 minutes yields cells that are noninfectious as assessed by extended infectivity assays. The psoralen/UV inactivation procedure described is effective with cells chronically or acutely infected with HIV-1 and is unaffected by cell densities up to 12 x 10(6)/ml. At 5 micrograms/ml psoralen does little damage to cellular permeability as shown by the ability of treated cells to exclude trypan blue and propidium iodide. Psoralen/UV treatment of HIV-1-infected cells does not cause a significant decrease in the reactivity of HIV-1 core and envelope antigens or cellular antigens to monoclonal antibodies. Experiments are presented demonstrating the use of these cells for flow cytometry studies and for cell surface labeling using the lactoperoxidase 125I iodination procedure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2340205     DOI: 10.1089/aid.1990.6.503

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  4 in total

1.  Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity.

Authors:  Aleksei F Bobkov; Ludmila M Selimova; Tatyana A Khanina; Sergey Y Zverev; Vadim V Pokrovsky; Jonathan N Weber; Eugene N Bobkov; Andrey V Rylkov
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Inhibition of virus production in peripheral blood mononuclear cells from human immunodeficiency virus (HIV) type 1-seropositive donors by treatment with recombinant HIV-like particles.

Authors:  O K Haffar; P A Moran; M D Smithgall; M L Diegel; P Sridhar; J A Ledbetter; J M Zarling; S L Hu
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

3.  Blood monocytes from most human immunodeficiency virus type 1-infected patients do not carry proviral DNA.

Authors:  Y Shen; J Rudnik; S Cassol; J Drouin; W Cameron; C A Izaguirre; L G Filion
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

4.  Bestatin-mediated inhibition of leucine aminopeptidase may hinder HIV infection.

Authors:  G Pulido-Cejudo; B Conway; P Proulx; R Brown; C A Izaguirre
Journal:  Antiviral Res       Date:  1997-12       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.